PTCT Upgraded by UBS -- Price Target Raised to $90.00
Alpha Vantage · GuruFocus · · AI-summarised by FinFlash
UBS upgraded PTC Therapeutics and raised its price target to $90.00, citing renewed confidence in the biotechnology company's development pipeline. GuruFocus data flags PTCT as 51.6% overvalued against a GF Value of $40.22, with a moderate GF Score of 59/100 on strong momentum but weak profitability and growth. Significant insider selling adds caution for investors weighing the upgrade.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.